Literature DB >> 15496267

Neurohormonal Therapy for Congestive Heart Failure.

Allison M Pritchett, Douglas L Mann.   

Abstract

Guidelines for heart failure management have been published by the American College of Cardiology and the American Heart Association in 2001. These guidelines recommend the use of angiotensin-converting enzyme inhibitors and beta blockers to improve the symptoms and prognosis of heart failure. Despite being advocated as the cornerstone of medical management, these agents remain underutilized. Not only are these drugs underutilized, but titration to dosages with proven beneficial effects is lacking. Simply achieving widespread usage of these agents would have a significant impact on heart failure outcomes.

Entities:  

Year:  2004        PMID： 15496267     DOI： 10.1007/s11936-004-0007-6

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


  38 in total

1.  Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2002-11-05       Impact factor: 25.391

Review 2.  15 years of heart-failure trials: what have we learned?

Authors:  B M Massie
Journal:  Lancet       Date:  1998-08       Impact factor: 79.321

3.  Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

4.  Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy.

Authors:  L W Stevenson; J H Tillisch; M Hamilton; M Luu; C Chelimsky-Fallick; J Moriguchi; J Kobashigawa; J Walden
Journal:  Am J Cardiol       Date:  1990-12-01       Impact factor: 2.778

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Authors:  W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

7.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

Authors:  M Packer
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

Review 8.  How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.

Authors:  M Packer
Journal:  Am J Cardiol       Date:  1993-03-25       Impact factor: 2.778

9.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors.

Authors:  B R Walker; M E Childs; E M Adams
Journal:  Am J Physiol       Date:  1988-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.